Form 4: Oncocyte CFO Andrea James Acquires 20,000 Shares of Common Stock

Oncocyte Corporation's Chief Financial Officer, Andrea James, purchased 20,000 shares of the company's common stock at a price of $2.29 per share.

Summary

• Andrea James, the Chief Financial Officer of Oncocyte Corporation, acquired 20,000 shares of common stock on December 5, 2024.
• The purchase price was $2.29 per share.
• Following this transaction, Ms. James directly owns 53,670 shares of Oncocyte common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction. While the purchase is a positive signal, it's not a major event that would significantly alter the sentiment.

Positives

• The purchase of shares by a company executive can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• The purchase of shares by a CFO is not unusual and is often seen as a sign of confidence in the company's future.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment, as it indicates confidence from a company executive.

Key Dates

Keywords

Oncocyte, insider trading, stock purchase, common stock, Andrea James, CFO, OCX